Key Takeaways
- •Cerebrolysin is a hydrolysate, not a molecule. It is made by controlled enzymatic breakdown of purified porcine brain proteins, so no single molecular formula, CAS number or mass describes it.
- •It is not authorized in Canada. An active-ingredient search of the Drug Product Database returns nothing, and the manufacturer, EVER Neuro Pharma, states that it is not marketed here.
- •The 2023 Cochrane review of acute stroke found no effect on death, across 7 trials and 1,773 participants, and moderate-certainty evidence of a possible increase in non-fatal serious adverse events.
- •The brain-injury and dementia results are small and uncertain. The CAPTAIN trials in traumatic brain injury reported a "small-to-medium" effect in 185 patients; the vascular dementia review called its evidence base "weak."
- •A purity percentage is the wrong measurement for it. Purity is a principal peak's share of the total, and a mixture has no principal peak by design.
- •Lot-to-lot consistency is the real analytical question, answered by comparing profiles rather than quoting a purity figure.
Summary
Cerebrolysin is a hydrolysate of purified pig brain protein: a mixture of short peptides and free amino acids rather than one molecule, so it has no CAS number, no formula and no meaningful purity percentage. It holds no Health Canada authorization and its manufacturer does not market it here, although it is used clinically in Russia, Eastern Europe and parts of Asia. The strongest independent review, Cochrane 2023 on acute ischaemic stroke, found no effect on death, and the brain-injury and dementia evidence is small and uncertain. For a lot of this material the useful questions are total peptide content, the molecular-weight profile and lot-to-lot consistency, not a single purity figure.
What is Cerebrolysin, and can you get it in Canada? It is not a peptide in the way the vials beside it are. It is a mixture made by enzymatic breakdown of purified pig brain protein, used clinically in Russia, Eastern Europe, China and other parts of Asia, and not authorized in Canada. Its clinical literature is the largest of any compound on a research-peptide shelf, and the most independent reviews of that literature have not found a benefit they would call established. Most Canadian pages selling it skip both points and print a purity percentage, which for a mixture is a number with nothing to measure.
This guide covers what Cerebrolysin is as a preparation, where it stands in Canada, what the stroke, brain-injury and dementia evidence actually concluded, how it differs from Semax and Selank, and what lot verification means for a material that is characterised rather than identified. It is written for laboratory and in-vitro research procurement. It reports what published studies recorded because that is the public evidence base, and it contains no dosing, administration or human-use guidance, and none should be inferred.
What Cerebrolysin Is
Cerebrolysin is made by digesting purified porcine brain protein with enzymes under controlled conditions, then filtering the result to keep the low-molecular-weight fraction. What remains is a mixture of short peptides and free amino acids. It is manufactured by EVER Neuro Pharma GmbH of Unterach, Austria.
| Property | Value |
|---|---|
| Material type | Peptide preparation from enzymatic protein hydrolysis |
| Biological source | Purified porcine brain protein |
| Manufacturer of the licensed product | EVER Neuro Pharma GmbH, Austria |
| CAS number | Not applicable |
| Molecular formula | Not applicable |
| Average mass | Not applicable |
| PubChem compound record | None under this name |
| Form | Lyophilized powder |
Every "not applicable" in that table is a positive statement about the material rather than a gap in our records. A registry number identifies a defined substance. A molecular formula counts the atoms in one molecule. A monoisotopic mass is the mass of one molecule's most abundant isotope pattern. None of those has a referent for a mixture of many peptides in varying proportions, and a supplier printing a CAS number for Cerebrolysin has either made one up or copied the number for something else.

Cerebrolysin vs Semax and Selank
The question comes up often enough to answer directly. Semax and Selank are single defined heptapeptides, seven residues each, with a known sequence, formula and mass. Semax is Met-Glu-His-Phe-Pro-Gly-Pro, an ACTH(4-10) analogue in which the last three residues are replaced by Pro-Gly-Pro; Selank is the immune peptide tuftsin with the same Pro-Gly-Pro tail. Cerebrolysin is the opposite kind of material: thousands of different fragments from a whole tissue, in proportions that move from lot to lot. They are sometimes sold side by side because all three come out of the Russian and Eastern European clinical tradition, not because they are chemically related.
Is Cerebrolysin Legal in Canada?
| Question | Answer |
|---|---|
| Drug Identification Number (DIN) | None |
| Notice of Compliance | None |
| Marketed in Canada | No, per the manufacturer |
| Authorized in the United States | No |
| Used clinically elsewhere | Yes, in Russia, Eastern Europe, China and other Asian countries |
| Lawfully sold or promoted for human use in Canada | No |
An active-ingredient search of the Health Canada Drug Product Database for cerebrolysin returns no result, so there is no DIN, no Notice of Compliance, and no product containing it may be sold as a drug in Canada. The manufacturer's own Canadian page says so plainly: "Cerebrolysin® is not marketed in Canada." Its site also carries a notice that the product "is not approved for sale or distribution in the United States."
This is the compound on the shelf where that answer most often surprises people, because it is in clinical use in a long list of other countries, including Austria, where its product information originates, and has a clinical literature running to hundreds of papers. Authorization is jurisdictional. A product licensed in Austria or Russia carries no standing in Canada, and a large foreign trial literature is not a Canadian marketing authorization. Health Canada's general position applies: it states that "it is illegal to sell or promote unauthorized health products in Canada," and the framework is set out in are peptides legal in Canada. For a Canadian buyer the position is the same as for any unauthorized compound: research material, laboratory use only.
One Canadian connection is real and worth stating accurately. The manufacturer promotes the inclusion of Cerebrolysin in the Canadian Evidence-Based Review of Stroke Rehabilitation (EBRSR), a literature review led by Robert Teasell. That is a review of evidence, not a Health Canada authorization, and the manufacturer's description of it is the manufacturer's.
What the Clinical Research Concluded
Cerebrolysin has the largest human literature of any compound covered in this series. The independent reviews of it are consistent: signals in some outcomes, no established benefit on the outcomes that matter most, and serious concerns about trial quality and sponsorship.
| Use | Best independent evidence | What it concluded |
|---|---|---|
| Acute ischaemic stroke | Cochrane review, 2023 (7 RCTs, 1,773 participants) | Probably little to no difference in all-cause death; possible increase in non-fatal serious adverse events |
| Traumatic brain injury | CAPTAIN prospective meta-analysis, 2021 (2 RCTs, 185 patients) | "Small-to-medium" effect on a combined functional and neuropsychological endpoint at days 30 and 90 |
| Vascular dementia | Cochrane review, 2019 | Effects on cognition, but "not definitive", high risk of bias, and possibly "too small to be clinically meaningful" |
| Stroke after thrombectomy | Observational cohorts and a 2026 meta-analysis of observational studies | Propensity-matched associations; no new randomised evidence |
Stroke: the Cochrane review
The Cochrane review of Cerebrolysin for acute ischaemic stroke was first published in 2010 and updated in 2015, 2016, 2017, 2020 and 2023. The 2023 update included seven randomised trials with 1,773 participants, one of them a trial of the cattle-derived Cerebrolysin-like product Cortexin. Its findings, in its own terms:
- Death: Cerebrolysin or Cortexin "probably result in little to no difference in all-cause death" (risk ratio 0.96, 95% CI 0.65 to 1.41; 6 trials, 1,689 participants; moderate certainty).
- Serious adverse events: little to no difference in the total number of people with serious adverse events, but an increase in the number with non-fatal serious adverse events (risk ratio 2.39, 95% CI 1.10 to 5.23; 3 trials, 1,335 participants; moderate certainty).
- What was not measured: none of the included studies reported poor functional outcome (death or dependence), early death, quality of life or time to return to work.
- Trial quality: the review judged selective outcome reporting unclear in every Cerebrolysin trial, and noted that the manufacturer supported three of the multicentre studies.
A question revisited six times over thirteen years without settling is itself information. How to weigh a trial literature like this one, and why the headline figure depends on how a trial counts the people who stopped, is taken up in reading peptide trial results.
Traumatic brain injury: the CAPTAIN trials
The CAPTAIN series was two phase IIIb/IV randomised, double-blind, placebo-controlled trials in moderate to severe traumatic brain injury, pooled in a prospective meta-analysis of 185 patients published in Neurological Sciences in 2021. The primary endpoint, an ensemble of functional and neuropsychological scales, showed a "small-to-medium" effect in favour of Cerebrolysin at day 30 and day 90, with comparable safety between groups. It is the strongest positive result in the literature, and it is small: 185 patients, a composite endpoint, and authors closely associated with the product's clinical programme.
Vascular dementia
The 2019 Cochrane review of Cerebrolysin for vascular dementia concluded that the included trials reported improvements on cognitive and global function scales, then qualified that immediately: the data "are not definitive," the included papers "had high risk of bias," and "if there are benefits of Cerebrolysin, the effects may be too small to be clinically meaningful." It described the supporting evidence base as "weak."
Why a Purity Percentage Does Not Apply
Chromatographic purity is computed as the area of the principal peak divided by the total peak area. It presumes there is a principal peak: one molecule that is supposed to be there, and a set of impurities that are not.
A hydrolysate inverts that premise. The many peptides in a Cerebrolysin lot are all supposed to be there. There is no single intended molecule and therefore no impurity fraction to measure against. Run on a reverse-phase column, the material produces a broad profile rather than one dominant peak, and whatever number a laboratory reported as "purity" would depend entirely on which peak it chose to treat as the principal one.
So the question to ask about a Cerebrolysin lot is not how pure it is. It is whether this lot resembles the last one. For a biologically sourced mixture that is answered by comparing profiles: the chromatographic fingerprint, the total peptide content, the free amino acid content, and the molecular-weight distribution of the peptide fraction. A 2024 paper in the Journal of Medicine and Life took this approach, comparing the composition and biological activity of Cerebrolysin with other peptide preparations, and a neurofilament-L reporter cell line has been described as a bioassay for quantifying neurotrophic activity in such preparations. That is the same distinction what actually proves a peptide sequence draws between identity and purity.

How to Verify a Cerebrolysin Lot
The verification questions for a hydrolysate differ from those for a defined peptide, and a certificate written for the latter will look complete while telling you almost nothing.
Ask what the preparation is, not how pure it is. The useful figures are total peptide content, the free amino acid fraction, and the molecular-weight distribution of the peptide fraction. Those describe the material. A single purity percentage does not.
Ask about the source and the process. The starting material is a biological tissue and the product is defined by its manufacturing process, so the process is part of its identity. A lot with no stated source material or hydrolysis process is not characterised.
Expect lot-to-lot variation, and expect it to be documented. Composition moves between batches. That is a property of the material rather than a defect, and it is a real experimental variable: an in-vitro result obtained with one lot may not reproduce with another. Record the lot number alongside every result.
Check the three things that make a certificate checkable:
- The laboratory is named, with its report number.
- The lot number on the document matches the vial in your hand.
- The laboratory publishes a verification page where the report number can be looked up independently.
Volta publishes its certificates as page images in its published certificate archive with the issuing laboratory's own verification link, and a certificate for the batch you receive is available on request. For this material in particular, read what the report measured rather than its headline figure, because the headline figure for a mixture is the least informative line on the page. The Canadian checklist is in how to verify a peptide in Canada, and the peptide testing labs directory lists independent laboratories.
Cerebrolysin Beside the Defined Peptides
Cerebrolysin is stocked as a single 60 mg vial and appears in no multi-component product, which is appropriate: combining a mixture of unknown composition with a defined peptide produces a material nobody can characterise. A reader comparing a 60 mg Cerebrolysin vial against a 10 mg vial of a defined peptide on price per milligram is comparing a mass of mixed material against a mass of one molecule, which is not a comparison. Related single-molecule compounds from the same clinical tradition are Semax and Selank.
Frequently Asked Questions
What is Cerebrolysin?
Cerebrolysin is a peptide preparation made by controlled enzymatic breakdown of purified porcine brain proteins, containing low-molecular-weight peptides and free amino acids. It is a mixture rather than a defined molecule, manufactured by EVER Neuro Pharma in Austria.
Is Cerebrolysin approved in Canada?
No. It has no Drug Identification Number and no Notice of Compliance, and the manufacturer states that it is not marketed in Canada. It cannot lawfully be sold or promoted as a medicine here, and it is supplied as a research material for laboratory use only.
Where is Cerebrolysin available as a medicine?
The 2023 Cochrane review describes it as widely used in Russia, Eastern Europe, China and other Asian and post-Soviet countries, and the manufacturer's product information is based on the Austrian Summary of Product Characteristics. It is not approved in Canada or the United States.
Why isn't Cerebrolysin approved in North America?
Neither Health Canada nor the FDA has authorized it, and the independent evidence does not establish a benefit on the outcomes regulators weigh most. The 2023 Cochrane review found no effect on death in acute stroke and a possible increase in non-fatal serious adverse events.
Is Cerebrolysin effective?
The independent reviews have not established that it is. In acute stroke the 2023 Cochrane review found little to no difference in death; in traumatic brain injury a 185-patient meta-analysis reported a small-to-medium effect on a composite score; in vascular dementia the Cochrane review called the evidence weak and any benefit possibly too small to matter clinically.
Is Semax the same as Cerebrolysin?
No. Semax is a single defined seven-residue peptide with a known sequence and mass. Cerebrolysin is a mixture of many peptides from digested brain protein. They are sometimes sold together because both come from the same clinical tradition.
Why does Cerebrolysin have no CAS number or molecular formula?
Because it is a mixture of many peptides in varying proportions. A CAS number identifies a defined substance and a molecular formula counts the atoms in one molecule, and neither applies to a hydrolysate. A CAS number printed for it would be wrong.
Can a purity percentage be reported for Cerebrolysin?
Not meaningfully. A hydrolysate has no principal peak by design, so any purity figure depends on which peak was chosen. The appropriate measurements are total peptide content, free amino acid content and the molecular-weight distribution of the peptide fraction.
Does lot-to-lot variation matter for in-vitro work?
Yes. The starting material is a biological tissue and the composition moves between batches, so a result obtained with one lot may not reproduce with another. Record the lot number alongside every result.
Sources
- Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. "Cerebrolysin for acute ischaemic stroke." Cochrane Database Syst Rev. 2023;10:CD007026. doi:10.1002/14651858.CD007026.pub7. PMID 37818733. Earlier versions: 2020 (PMID 32662068), 2017 (PMID 28430363), 2016 (PMID 27918088), 2015 (PMID 26083192), 2010 (PMID 20393954).
- Vester JC, Buzoianu AD, Florian SI, et al. "Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series." Neurol Sci. 2021;42(11):4531-4541. PMID 33620612.
- Cui S, Chen N, Yang M, et al. "Cerebrolysin for vascular dementia." Cochrane Database Syst Rev. 2019;(11):CD008900. PMID 31710397.
- EVER Neuro Pharma. "Canadian stroke rehabilitation guidelines" (cerebrolysin.com, 30 October 2020) and "About Cerebrolysin" (product information based on the Austrian Summary of Product Characteristics).
- Health Canada Drug Product Database, active-ingredient search for cerebrolysin: no result returned, checked 6 November 2026.
- Health Canada. "Peptides: Regulations and enforcement." Canada.ca, page details 23 October 2026.
- PubChem: no compound record returned for the name Cerebrolysin, checked 6 November 2026, the expected result for a protein hydrolysate.
- "Comparing the biological activity and composition of Cerebrolysin with other peptide preparations." Journal of Medicine and Life. 2024. PMID 38737662.
- "A Neurofilament-L reporter cell line for the quantification of early neuronal differentiation: A Bioassay for neurotrophic activities." Heliyon. 2024. PMID 38304771.
- "Cerebrolysin after Endovascular Thrombectomy in Stroke: 12-Month Functional Outcomes in a Propensity-Matched Cohort." Translational Stroke Research. 2026. PMID 41739286.
- "Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies." Brain and Behavior. 2026. PMID 41880098.

